Phase 2 study of oral sabizabulin for the treatment of SARS-CoV-2 in hospitalized patients at high risk for ARDS

Gordon, M., European Congress of Clinical Microbiology & Infectious Diseases, Apr 2022
Late treatmentDouble-blind RCT · USA
Sabizabulin for COVID-19
Gordon, M. European Congress of Clinical Microbiology & Infectio.. · Apr 2022
Outcome
Improvement
Relative Risk · 95% CI
Lower mortality and shorter ICU admission
p = 0.042 (mortality) and p = 0.026 (ICU admission)

Antiandrogens for COVID-19

7th treatment shown to reduce risk in September 2020, now with p = 0.000000056 from 49 studies.

No treatment is 100% effective.
Protocols combine treatments.

Phase 2 RCT of sabizabulin showing lower mortality with treatment. For more discussion see1.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments2. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
OutcomeImprovementEffect · pTreatmentControl
risk of death 82.0% lower · RR 0.18 · p = 0.04* 82.0% lowerRR 0.18p = 0.04* , ITT
ventilation time 76.5% lower · relative time 0.24 · p = 0.14 76.5% lowerrelative time 0.24p = 0.14 ,
ICU time 72.9% lower · relative time 0.27 · p = 0.03* 72.9% lowerrelative time 0.27p = 0.03* ,

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05

Gordon et al., 25 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 1 author.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective